Cannabis and work: Need for more research.
Journal
American journal of industrial medicine
ISSN: 1097-0274
Titre abrégé: Am J Ind Med
Pays: United States
ID NLM: 8101110
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
27
07
2020
revised:
04
08
2020
accepted:
05
08
2020
pubmed:
17
8
2020
medline:
17
8
2021
entrez:
16
8
2020
Statut:
ppublish
Résumé
Cannabis sativa is one of the oldest and most widely used plants in the world with a variety of industrial, medical, and nonmedical applications. Despite its long history, cannabis-derived products remain a source of controversy across the fields of medicine, law, and occupational safety and health. More favorable public attitudes about cannabis in the US have resulted in greater access to cannabis through legalization by states, leading to more consumption by workers. As more states adopt cannabis access laws, and as more workers choose to consume cannabis products, the implications for existing workplace policies, programs, and practices become more salient. Past workplace practices were grounded in a time when cannabis consumption was always viewed as problematic, considered a moral failing, and was universally illegal. Shifting cultural views and the changing legal status of cannabis indicate a need for research into the implications and challenges relating to cannabis and work. This commentary suggests research needs in the following areas: (a) data about industries and occupations where cannabis consumption among workers is most prevalent; (b) adverse health consequences of cannabis consumption among workers; (c) workplace supported recovery programs; (d) hazards to workers in the emerging cannabis industry; (e) relationship between cannabis consumption and occupational injuries; (f) ways to assess performance deficits and impairment from cannabis consumption; (g) consumption of synthetic cannabinoids to evade detection by drug testing; (h) cannabis consumption and its effect on occupational driving; and (i) ways to craft workplace policies and practices that take into consideration conflicting state and federal laws pertaining to cannabis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
963-972Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Khalsa JH, Bunt GC, Galantier M, Wetterau NW. Medicinal uses of cannabis and cannabinoids. In: Miller SC, Fiellin DA, Rosenthal RH, Saitz R, eds. The ASAM Principles of Addiction Medicine. 6th ed. Philadelphia, PA: Wolters-Kluwer; 2019:1744-1751.
Lapoint JM. Cannabinoids. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, eds. Goldfrank's Toxicologic Emergencies. 10th ed. New York, NY: McGraw-Hill; 2015:1042-1053.
Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614-1648. https://doi.org/10.1002/cbdv.200790144
Bennett C. Early/ancient history. In: Holland J, ed. The Pot Book: A Complete Guide to Cannabis. Rochester, NY: Vermont: Park Street Press; 2010:17-26.
Goldsmith RS, Targino MC, Fanciullo GJ, et al. Medical marijuana in the workplace: challenges and management options for occupational physicians. J Occup Environ Med. 2015;57(5):518-525. https://doi.org/10.1097/JOM.0000000000000454
Solomon R. Racism and its effect on cannabis research. Cannabis Cannabinoid Res. 2020;5(1):2-5. https://doi.org/10.1089/can.2019.0063
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. 2019. HHS Publication No. PEP19-5068, NSDUH Series H-54. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf. Accessed July 27, 2020.
Hasin DS, Sarvet AL, Cerdá M, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws, 1991-1992 to 2012-2013. JAMA Psychiatry. 2017;74(6):579-588. https://doi.org/10.1001/jamapsychiatry.2017.0724
Substance Abuse and Mental Health Services Administration. Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Section 7 Prevalence Estimates Tables. 2019. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2018R2/NSDUHDetTabsSect7pe2018.htm. Accessed July 27, 2020.
National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017. https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state. Accessed July 27, 2020.
Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2773. https://doi.org/10.1001/jama.2015.6358
Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observation studies. Pain. 2018;159(10):1932-1954. https://doi.org/10.1097/j.pain.0000000000001293
Mücke M, Phillips T, Radbruch L, Petzke F, Hauser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Sys Rev. 2018;3(3):CDO12182. https://doi.org/10.1002/14651858.CD012182.pub2
Memedovich KA, Dowsett LE, Spackman E, Noseworthy T, Clement F. The adverse health effects and harms related to marijuana use: an overview review. Can Med Assoc J Open. 2018;6(3):E339-E346. https://doi.org/10.9778/cmajo.20180023
National Institute on Drug Abuse. Marijuana Research Report. Revised July 2020. https://www.drugabuse.gov/publications/research-reports/marijuana/what-scope-marijuana-use-in-united-states. Accessed July 27, 2020.
Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1-8. https://doi.org/10.1097/ADM.0b013e31820c23fa
Volkow N, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219-2227. https://doi.org/10.1056/NEJMra1402309
National Safety Council. Research Document: Marijuana and Driving. Itasca, Ill: National Safety Council; September 2017. https://www.nsc.org/Portals/0/Documents/NSCDocuments_Advocacy/Divisions/ADID/Position-on-Cannabis-and-Driving.pdf. Accessed July 27, 2020.
Kuddus M, Ginawi IAM, Al-Hazimi A. Cannabis sativa: an ancient wild edible plant of India. Emir J Food Agric. 2013;25:736-745. https://doi.org/10.9755/ejfa.v25i10.16400
Lash R. Industrial hemp: the crop for the seventh generation. Am Ind Law Rev. 2002;27(1):313-356. https://core.ac.uk/download/pdf/217219179.pdf. Accessed July 27, 2020.
Agricultural Improvement Act of 2018, P.L. 115-334. 7 U.S.C. Chapter 38, Subchapter VII (Hemp Production), §1639o (Definitions). https://uscode.house.gov/view.xhtml?path=/prelim@title7/chapter38/subchapter7&edition=prelim. Accessed July 27, 2020.
Johnson R. Defining hemp: a fact sheet. Congressional Research Service. R44742. March 22, 2019. https://crsreports.congress.gov/product/pdf/R/R44742. Accessed July 27, 2019.
Russo E. Cannabis in India: ancient lore and modern medicine. In: Mechoulam R, ed. Cannabinoids as Therapeutics. New York, NY: Springer; 2005:1-22.
Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been. Headache. 2015;55(6):885-916. https://doi.org/10.1111/head.12570
Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. Pharm Ther. 2017;42(3):180-188. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312634/
Welch SP, Smith TH, Malcolm R, Lichman AH. The pharmacology of cannabinoids. In: Miller SC, Fiellin DA, Rosenthal RN, Saitz R, eds. The ASAM Principles of Addiction Medicine. 6th ed. Philadelphia, PA: Wolters-Kluwer; 2019:208-229.
Pertwee RG. Endocannabinoids and their pharmacological actions. Handb Exp Pharmcol. 2015;231:1-37. https://doi.org/10.1007/978-3-319-20825-1_1
VanDolah HJ, Bauer BA, Mauck KF. Clinician's guide to cannabidiol and hemp oils. Mayo Clin Proc. 2019;94(9):1840-1851. https://doi.org/10.1016/j.mayocp.2019.01.003
Mechoulam R, Harius LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014;15(11):757-764. https://doi.org/10.1038/nrn3811
Wu I. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow. Act Pharmacol Sin. 2019;40(3):297-299. https://doi.org/10.1038/s41401-019-0210-3
Grof CPL. Cannabis, from plant to pill. Br J Clin Pharmacol. 2018;84:2463-2467. https://doi.org/10.1111/bcp.13618
World Health Organization (WHO). Cannabidiol (CBD): World Health Organisation Expert Committee on Drug Dependence Thirty-Ninth Meeting. 2017. https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf. Accessed July 27, 2020.
Eisenstein M. The reality behind cannabidiol's medical hype. Nature. 2019;572:S2-S4. https://www.nature.com/articles/d41586-019-02524-5. Accessed July 27, 2020.
Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. 2020;411:116717-116723. https://doi.org/10.1016/j.jns.2020.116717
U.S. Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. January 14, 2020. https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process. Accessed July 27, 2020.
Badowksi ME, Yanful PK. Dronabinol oral solutions in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag. 2018;14:643-651. https://doi.org/10.2147/TCRM.S126849
Pergolizzi JV, Taylor R, LeQuang JA, Zampogna G, Raffa RB. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2017;79(3):467-477. https://doi.org/10.1007/s00280-017-3257-1
Abu-Sawwa R, Stehling C. Epidiolex (cannabidiol) primer: frequently asked questions for patients and caregivers. J Pediatr Pharmacol Ther. 2020;25(1):75-77. https://doi.org/10.5863/1551-6776-25.1.75
ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613-619. https://doi.org/10.1016/j.biopsych.2016.01.004
Cash MC, Cunnane K, Romero-Sandoval EA. Mapping cannabis potency in medical and recreational programs in the United States. PLoS One. 2020;25(3):e023167. https://doi.org/10.1371/journal.pone.0230167
Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addict. 2017;112:2167-2177. https://doi.org/10.1111/add.13886
Stroger JM, Miller BL. Assessing the dangers of “dabbing”: mere marijuana or harmful new trend? Pediatrics. 2015;136(1):1-3. https://doi.org/10.1542/peds.2015-0454
Sagar KA, Lambros AM, Dahlgren MK, Smith RT, Gruber SA. Made from concentrate? A national web survey assessing dab use in the United States. Drug Alc Depend. 2018;190:133-142. https://doi.org/10.1016/j.drugalcdep.2018.05.022
Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45:3181-3189. https://doi.org/10.1017/S0033291715001178
Bidwell LC, Ellingson JM, Karoly HC, et al. Association of naturalistic administration of cannabis flower and concentrates with intoxication and impairment [published online ahead of print June 10, 2020]. JAMA Psychiatry. 2020:0927. https://doi.org/10.1001/jamapsychiatry
Hall KE, Monte AA, Chang T, et al. Mental health emergency department visits associated with cannabis in Colorado. Acad Emerg Med. 2018;25:526-537. https://doi.org/10.1111/acem.13393
Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med. 2019;170:531-537. https://doi.org/10.7326/M18-2809
Allen JH, de Moore JM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53(11):209-217. https://doi.org/10.1136/gut.2003.036350
DeVuono MV, Parker LA. Cannabinoid hyperemesis syndrome: a review of potential mechanisms. Cannabis Cannabinoid Res. 2020;5(2):132-144. https://doi.org/10.1089/can.2019.0059
Nourbakhsh M, Miller A, Gofton J, Jones G, Adeago B. Cannabinoid hyperemesis syndrome: reports of fatal cases. J Forensic Sci. 2019;64(1):270-274. https://doi.org/10.1111/1556-4029.13819
Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Prac. 2007;4(1):4-16. https://pubmed.ncbi.nlm.nih.gov/18292704/
Hasin DS, Keyes KM, Alderson D, Wang S, Aharonvich E, Grant BF. Cannabis withdrawal in the United States: results in from NESARC. J Clin Psychiatry. 2008;69:1354-1363. https://doi.org/10.4088/jcp.v69n0902
Gorelick DA, Levin KH, Copersino ML, et al. Diagnostic criteria for cannabis withdrawal syndrome. Drug Alcohol Depend. 2012;123:141-171. https://doi.org/10.1016/j.drugalcdep.2011.11.007
Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37. https://doi.org/10.2147/SAR.S109576
American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®), 304.20, 304.30. 5th ed. Arlington, VA: American Psychiatry Publishing; 2013.
Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242. https://doi.org/10.1001/jamapsychiatry.2015.1858
Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: current science and outlook. Pharmacol. 2016;36(5):511-535. https://doi.org/10.1002/phar.1747
Hasin DS. US epidemiology of cannabis use and associated problems. Neuropsychopharmacol. 2018;43:195-212. https://doi.org/10.1038/npp.2017.198
Patel J, Marwaha R. Cannabis use disorder. National Library of Medicine. Bethesda, MD: StatPearls Publishing; June 5, 2019. https://www.ncbi.nlm.nih.gov/books/NBK538131/?report=printable. Accessed July 27, 2020.
Laudet AB. Rate and predictors of employment among formerly polysubstance dependent urban individuals in recovery. J Addict Dis. 2012;31(3):288-302. https://doi.org/10.1080/10550887.2012.694604
National Drug Control Strategy. National Treatment Plan for Substance Use Disorder 2020. Washington, DC: Office of National Drug Control Policy February, 2020; 2020. https://www.whitehouse.gov/wp-content/uploads/2020/02/2020-NDCS-Treatment-Plan.pdf
Developing a workplace supported recovery program: a strategy for assisting workers and employers with the nation's opioid and substance use disorder epidemics: request for information. Fed Regist. 2020;85(38):11085-11086 (February 26, 2020). https://www.govinfo.gov/content/pkg/FR-2020-02-26/pdf/2020-03785.pdf. Accessed July 27, 2020.
Bottino B. Cannabis worker safety. Safety+Health Magazine. November 24, 2019. https://www.safetyandhealthmagazine.com/articles/print/19117-cannabis-worker-safety. Accessed July 27, 2020.
Colorado Department of Public Health and Environment. Guide to worker safety and health in the marijuana industry. Denver, CO: State of Colorado; 2017. https://deohs.washington.edu/sites/default/files/documents/Guide-to-Worker-Safety-and-Health-in-the-Marijuana-Industry_FULL-REPORT.pdf. Accessed July 27, 2020.
Couch J, Grimes GR, Green BJ, Wiegand DM, King B, Methner MM. Review of NIOSH cannabis-related health hazard evaluations and research [published online ahead of print February 13, 2020]. Ann Work Exposures Health. 2020;64:693-704. https://doi.org/10.1093/annweh/wxaa013
Wiegand DM, Methner MM, Grimes R. Evaluation of police officers’ exposure to secondhand cannabis smoke at open-air stadium events. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Health Hazard Evaluation Report 2017-0174-3335; March, 2019. https://www.cdc.gov/niosh/hhe/reports/pdfs/2017-0174-3335.pdf. Accessed July 27, 2020.
Fent K, Durgam S, West C, Gibbins J, Smith J. Evaluation of police officer's exposures to chemicals while working inside a drug vault-Kentucky. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, HHE Report No. 2010-0017-3133; July 2011 https://www.cdc.gov/niosh/hhe/reports/pdfs/2010-0017-3133.pdf. Accessed July 27, 2020.
Vernon A. Marijuana: a growing hazard on the fireground. Firehouse. July 10, 2009. https://www.firehouse.com/safety-health/article/10471249/marijuana-a-growing-hazard-on-the-fireground. Accessed July 27, 2020.
Phillips JA, Holland MG, Baldwin DD, et al. Marijuana in the workplace: guidance for occupational health professionals and employers. Joint guidance statement from the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine. Workplace Health Saf. 2015;63(4):139-164. https://doi.org/10.1177/2165079915581983
Parnes JE, Bravo AJ, Conner BT, Pearson MR. A burning problem: cannabis lessons learned from Colorado. Addict Res Theory. 2018;26(1):3-10. https://doi.org/10.1080/16066359.2017.1315410
Hartman RJ, Huestis MA. Cannabis effects on driving skills. Clin Chem. 2013;59(3):478-492. https://doi.org/10.1373/clinchem.2012.194381
Desrosiers NA, Ramaekers JG, Chauchard E, Gorelick DA, Huestis MA. Smoked cannabis’ psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol. 2015;39(4):251-261. https://doi.org/10.1093/jat/bkv012
Biasutti WR, Leffers KSH, Callaghan RC. Systematic review of cannabis use and risk of occupational injury [published online ahead of print May 22, 2020]. Subst Use Misuse. 2020. https://doi.org/10.1080/10826084.2020.1759643
Frone MR. Workplace interventions I: drug testing job applicants and employees. In: Frone MR, ed. Alcohol and Illicit Drug Use in the Workforce and Workplace. Washington, DC: American Psychological Association; 2013:143-175. https://doi.org/10.1037/13944-006
Reisfield GM, Bertholf RL, Goldberger BA, DuPont RL. Practical considerations in drug testing. In: Miller SC, Fiellin DA, Rosenthal RN, Saitz E, eds. The ASAM Principles of Addiction Medicine. 6th ed. Philadelphia, PA: Wolters-Kluwer; 2019:1752-1767.
Drug Free Workplace Act of 1988. Title 41, United States Code, § 8101 et seq. https://uscode.house.gov/view.xhtml?path=/prelim@title41/subtitle4/chapter81&edition=prelim. Accessed July 27, 2020.
U.S. Department of Transportation. Procedures for Transportation Workplace Drug and Alcohol Testing Programs. Title 40, Code of Federal Regulations, Part 40. Omnibus Transportation Employee Testing Act of 1991, 49 U.S.C. § 5331. https://www.transportation.gov/odapc/part40. Accessed July 27, 2020.
Connors N, Kosnett MJ, Kulig K, Nelson LS, Stolbach AI. ACMT position statement: interpretation of urine tetrahydrocannabinol metabolites. J Med Toxicol. 2020;16:240-242. https://doi.org/10.1007/s13181-019-00753-8
Reisfield GM, Goldberger BA, Gold MS, DuPont RL. The mirage of impairing drug concentration thresholds: a rationale for zero tolerance per se driving under the influence of drug laws. J Anal Toxicol. 2012;36:353-356. https://doi.org/10.1093/jat/bks037
Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009;23:266-277. https://doi.org/10.1177/0269881108092393
Macdonald S, Hall W, Roman P, Stockwell T, Coghlan M, Nesvaag S. Testing for cannabis in the workplace: a review of the evidence. Addiction. 2010;105:408-416. https://doi.org/10.1111/j.1360-0443.2009.02808.x
Hickox SA. Drug testing of medical marijuana users in the workplace: An inaccurate test of impairment. Hofstra Labor and Employment Law Review. 2012;29(2):273-341. https://law.hofstra.edu/pdf/academics/journals/laborandemploymentlawjournal/labor_vol29no2_hickox_format.pdf. Accessed July 27, 2020.
Pidd K, Roche A. How effective is drug testing as a workplace safety strategy? A systematic review of the evidence. Accid Anal Prev. 2014;71:154-165. https://doi.org/10.1016/j.aap.2014.05.012
Greenfield R, Kaplan J. The coming decline of the employment drug test. Bloomberg News. March 5, 2018. https://www.bloomberg.com/news/articles/2018-03-05/the-coming-decline-of-the-employment-drug-test. Accessed July 27, 2020.
Butler B, Tranter D. Behavioral tests to assess performance. In: Macdonald S, Roman P, eds. Research Advances in the Workplace: Volume II. Drug Testing in the Workplace. New York: Plenum Press; 1994:231-255.
Schroth LA, Hody BJ, Chaffin CS, Laratonda E, Cook GW. Medical marijuana. Addressing impairment in the workplace. Prof Saf. 2018;63(8):36-40. https://www.onepetro.org/journal-paper/ASSE-18-08-36. Accessed July 27, 2020.
Malty L. Impairment testing-does it work? National Workrights Institute. Princeton, New Jersey; 2001. https://www.workrights.org/nwi_drugTesting_impairmentTesting.html. Accessed July 27, 2020.
Ferguson BA, Lauriski DR, Huecker M, Wichmann M, Shreffler J, Shoff H. Testing alertness of emergency physicians: a novel quantitative measure of alertness and implication for worker and patient care. J Emerg Med. 2020;58(2):514-519. https://doi.org/10.1016/j.jemermed.2019.10.032
Mannion A. Effective cannabis testing in the workplace: no, we are not there yet. Risk & Insurance, June 10, 2019. https://riskandinsurance.com/cannabis-impairment-testing/. Accessed July 27, 2020.
Crews BO. Synthetic cannabinoids: the challenge of testing for designer drugs. AACC Clinical Laboratory News; February 1, 2013. https://www.aacc.org/publications/cln/articles/2013/february/cannabinoids. Accessed July 27, 2020.
ElSohly MA, Gul W, Wanas AS, Radwah MM. Synthetic cannabinoids: analysis and metabolites. Life Sci. 2014;97(1):78-90. https://doi.org/10.1016/j.lfs.2013.12.212
Castaneto MS, Wohlfarth A, Desrosiers NA, Hartman RL, Gorelick DA, Huestis MA. Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. Drug Metab Rev. 2015;47(2):124-174. https://doi.org/10.3109/03602532.2015.1029635
Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol. 2015;33:175-194. https://doi.org/10.1007/s11419-015-0270-0
Peacock A, Bruno R, Gisev N, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668-1684. https://doi.org/10.1016/S0140-6736(19)32231-7
National Institute on Drug Abuse. Synthetic cannabinoids (K2/Spice). February 2018. https://www.drugabuse.gov/drug-topics/synthetic-cannabinoids-k2spice. Accessed July 27, 2020.
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoid: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12-41. https://doi.org/10.1016/j.drugalcdep.2014.08.005
Abdulrahim D, Bowden-Jones O, on behalf of NEPTUNE group. Harms of Synthetic Cannabinoid Receptor Agonists (SCRAs) and Their Management. London: Novel Psychoactive Treatment UK Network (NEPTUNE), 2016. http://neptune-clinical-guidance.co.uk/wp-content/uploads/2016/07/Synthetic-Cannabinoid-Receptor-Agonists.pdf. Accessed July 27, 2019.
Papanti D, Schifano F, Botteon G, et al. “Spiceophrenia:” A systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28(4):379-389. https://doi.org/10.1002/hup.2312
Davidson C, Opacka-Juffry J, Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E, Molina-Holgado F. Spicing up pharmacology: a review of synthetic cannabinoids from structure to adverse events. Adv Pharmcol. 2017;80:136-166. https://doi.org/10.1016/bs.apha.2017.05.001
Umut G, Evren C, Atagun MI, et al. Impact of at least 2 years of synthetic cannabinoid use on cognitive and psychomotor functions among treatment-seeking male outpatients. Cannabis Cannabinoid Res. 2020;5(2):164-171. https://doi.org/10.1089/can.2019.0017
Law R, Schier J, Martin C, Chang A, Wolkin A. Notes from the field: Increase in reported adverse health effects related to synthetic cannabinoid use-United States, January-May 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):618-619. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6422a5.htm. Accessed July 27, 2020.
Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. December 4, 2012. Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids. Rockville, MD. https://www.samhsa.gov/data/sites/default/files/DAWN105/DAWN105/SR105-synthetic-marijuana.pdf. Accessed July 27, 2020.
Bush DM, Woodwell DA Update: Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids. In: The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US), 2014:1-10. https://pubmed.ncbi.nlm.nih.gov/27030867/. Accessed July 27, 2020.
Stackhouse TP. Regulators in wackyland: capturing the last of the designer drugs. Arizona L Rev. 2012;54:1105-1137. https://arizonalawreview.org/stackhouse
Ramsey JG, Tapp L, Burr G Evaluation of law enforcement agents’ potential exposure to a raid of a clandestine “spice” lab. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, HHE Report No. 2014-0039-3246; March, 2016. https://www.cdc.gov/niosh/hhe/reports/pdfs/2014-0039-3246.pdf. Accessed July 27, 2020.
Azofeifa A, Rexach-Guzman BD, Hagemeyer AN, Rudd RA, Sauber-Schatz EK. Driving under the influence of marijuana and illicit drugs among persons aged > 16 years-United States, 2018. MMWR Morbid Mortal Wkly Rep. 2019;68(50):1153-1157. https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6850a1-H.pdf. Accessed July 27, 2020.
Berghaus G, et al. Meta-analysis of empirical studies concerning the effects of medicines and illegal drugs including pharmacokinetics on safe driving. DRUID 6th Framework Programme: Germany: European Commission under the Transport RTD Programme of the 6th Framework Programme, 2011;168-172. https://www.bast.de/Druid/EN/deliverales-list/downloads/Deliverable_1_1_2_B.pdf?__blob=publicationFile&v=1. Accessed July 27, 2020.
Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. Brit Med J. 2012:344. https://doi.org/10.1136/bmj.e536
Asbridge M, Mann R, Cusimano MD, et al. Cannabis and traffic collision risk: findings from a case-crossover study of injured drivers presenting to emergency departments. Int J Public Health. 2014;59:395-404. https://doi.org/10.1007/s00038-013-0512-z
Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collisions revisited and revised. Addict. 2016;111:1348-1359. https://doi.org/10.1111/add.13347
Macdonald S. Cannabis Crashes. Myths & Truths. Raleigh, NC: Lulu Publishing; 2018.
Laumon B, Gadegbeku B, Martin J-L, Biecheler M-B, the SAM Group. Cannabis intoxication and fatal road crashes in France: population-based case-control study. BMJ. 2005;331:1371-1377. https://doi.org/10.1136/bmj.38648.617986.1F
Papafotiou K, Carter JD, Stough C. The relationship between performance on the standardized field sobriety tests, driving performance and the level of delta-9-tetraydrocannabinol (THC) in blood. Forensic Sci Int. 2005;155:172-178. https://doi.org/10.1016/j.forsciint.2004.11.009
Ramaekers JG, Moeller MR, van Ruitenbeck P, Theunissen EL, Schneider E, Kauert. Cognition and motor control as a function of delta-9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend. 2006;85:114-122. https://doi.org/10.1016/j.drugalcdep.2006.03.015
Wong K, Brady JE, Li G. Establishing legal limits for driving under the influence of marijuana. Injury Epidemiol. 2014;1(1):26-34. https://doi.org/10.1186/s40621-014-0026-z
Marijuana Drug-Impaired Driving Laws. Washington, DC: Governors Highway Safety Association. https://www.ghsa.org/state-laws/issues/drug%20impaired%20driving. Accessed July 27, 2020.
Compton R. Marijuana-impaired driving. A report to Congress. DOT HS 812 440). Washington, DC: National Highway Traffic Safety Administration; July 2017. https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/documents/812440-marijuana-impaired-driving-report-to-congress.pdf. Accessed July 27, 2020.
Beck O. Exhaled breath for drugs of abuse testing-evaluation in criminal justice settings. Sci Justice. 2014;54(1):57-60. https://doi.org/10.1016/j.scijus.2013.09.007
Himes SK, Scheidweiler KB, Beck O, Gorelick DA, Desrosiers NA, Huestis MA. Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem. 2013;59(12):1780-1789. https://doi.org/10.1373/clinchem.2013.207407
Marihuana Tax Act of 1937, Pub. L. No. 75-238, ch. 553, 50 Stat. 551 (repealed 1970). http://www.druglibrary.org/schaffer/hemp/taxact/mjtaxact.htm. Accessed July 27, 2020.
Controlled Substances Act. 21 U.S.C. § 801 et seq. (Pub. L. 91-513). https://uscode.house.gov/view.xhtml?path=/prelim@title21/chapter13&edition=prelim. Accessed July 27, 2020.
Denial of petition to initiate proceedings to reschedule marijuana. Fed Regist. 2016;81(156):53688-53766 (August 12, 2016). https://www.govinfo.gov/content/pkg/FR-2016-08-12/pdf/2016-17954.pdf. Accessed July 27, 2020.
National Conference of State Legislatures. State Medical Marijuana Laws. March 10, 2020. https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Accessed July 27, 2020.
Qualifying conditions for medical marijuana by state. Leafly. January 29, 2020. https://www.leafly.com/news/health/qualifying-conditions-for-medical-marijuana-by-state. Accessed August 4, 2020.
Marijuana Overview. National Conference of State Legislatures. October 17, 2019. https://www.ncsl.org/research/civil-and-criminal-justice/marijuana-overview.aspx. Accessed August 4, 2020.
Assembly Bill 132. State of Nevada. June 5, 2019 approved by the Governor. https://www.leg.state.nv.us/App/NELIS/REL/80th2019/Bill/6191/Text. Accessed July 27, 2020.
Russo KJ. New York City Human Rights Law Ban On Pre-Employment Marijuana Testing Takes Effect. National Law Review. July 27, 2020. https://www.natlawreview.com/article/new-york-city-human-rights-law-ban-pre-employment-marijuana-testing-takes-effect. Accessed July 27, 2020.
Mikos RA. Marijuana Law, Policy, and Authority. New York, NY: Wolters Kluwer; 2017:662-665.
Moreno JA. Half-baked: the science and politics of legal pot. Penn State Law Rev. 2019;123(2):401-462. https://ecollections.law.fiu.edu/faculty_publications/398/. Accessed July 27, 2020.
Duke SB. The future of marijuana in the United States. Oregon Law Rev. 2013;91:1301-1318. https://digitalcommons.law.yale.edu/fss_papers/4842/. Accessed July 27, 2020.
Hall W, Stjepanović D, Caulkins J, et al. Public health implications of legalizing the production and sale of cannabis for medicinal and recreational use. Lancet. 2019;394(10208):1580-1590. https://doi.org/10.1016/S0140-6736(19)31789-1
McGinty EE, Samples H, Bandara S, Saloner B, Bachhuber M, Barry CL. The emerging public discourse on state legalization of marijuana for recreational use in the US: analysis of news media coverage, 2010-2014. Prev Med. 2016;90:114-120. https://doi.org/10.1016/j.ypmed.2016.06.040
Kleiman MAR. The public-health case for legalizing marijuana. Nat Affairs. 2020;42:68-83. Winter. https://www.nationalaffairs.com/publications/detail/the-public-health-case-for-legalizing-marijuana. Accessed July 27, 2020.